Li Hongsen
Partner @ Golden Rain Bogor
Li Hongsen is a partner of Golden Rain Bogor.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Li Hongsen invests in
Stages Li Hongsen invests in
Countries Li Hongsen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (60%)
- Pharmaceutical 3 (60%)
- Medical 2 (40%)
- Health Care 2 (40%)
- Manufacturing 2 (40%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Angel 1 (20%)
- Series B 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Butterfly is a manufacturer of prefilled syringes. It focuses on using the next-generation high-performance materials COC&COP to produce prefilled syringes without silicone oil systems, and is committed to breaking the international monopoly and promoting the material revolution in China's pharmaceutical packaging industry. | Angel / Mar 03, 2025 | ||
Xiushi Biotechnology
|
Xiushi Biotechnology Focus on the R&D, production, sales, and technology development services of peptide products. | $14.2M / Seed / Oct 08, 2024 | |
| Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services. | $14.1M / Series A / Dec 14, 2023 | ||
| Boyi Biotechnology is a technology-based firm that provides vital raw materials and complete solutions to biomedical customers in the in vitro diagnostic market. It focus on diagnostic microspheres, testing raw materials, and quality control products. | $14.1M / Series A / May 30, 2023 | ||
| ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14M / Series B / Sep 26, 2022 |
Co-Investors
About Golden Rain Bogor
Jinyu Bogor focuses on strategic emerging industries such as medical and pharmaceutical general health.
Golden Rain Bogor Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Li Hongsen
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Li Hongsen invest in?
Li Hongsen invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Li Hongsen?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Li Hongsen last invest?
The most recent investment recorded for Li Hongsen closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
